Accession Number : ADA625990


Title :   Intravesical NGF Antisense Therapy Using Lipid Nanoparticle for Interstitial Cystitis


Descriptive Note : Annual rept. 30 Sep 2014-29 Sep 2015


Corporate Author : LIPELLA PHARMACEUTICALS INC PITTSBURGH PA


Personal Author(s) : Chancellor, Michael ; Yoshimura, Naoki ; Gruber, Michele ; Chancellor, David


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/a625990.pdf


Report Date : Oct 2015


Pagination or Media Count : 68


Abstract : Interstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating disorder characterized by persistent pelvic pain associated with bladder symptoms including urinary frequency and urgency. Previous studies have indicated that overexpression of nerve growth factor (NGF) is a important factor in the symptom development of IC/BPS. This project evaluates the feasibility of an anti-NGF bladder drug delivery system as a potential investigational drug product. The project aims include exploration, manufacture, characterization, and nonclinical animal testing of a liposome NGF-antisense formulation targeting IC/BPS. During the project period investigators conducted nonclinical experiments and analyzed results from an animal efficacy experiment conducted during the previous period. The project is ongoing.


Descriptors :   *ANTISENSE THERAPY , *BLADDERS , *LIPIDS , *NANOPARTICLES , *UROLOGY , CLINICAL MEDICINE , CYTOPLASM , DELIVERY , DRUGS , EXPERIMENTAL DESIGN , FEASIBILITY STUDIES , GROWTH(PHYSIOLOGY) , INFLAMMATION , INTERSTITIAL , LIPOSOMES , MICE , NERVES , PAIN , PELVIS , RECEPTOR SITES(PHYSIOLOGY) , RESPONSE(BIOLOGY) , RIBONUCLEIC ACIDS , SIGNS AND SYMPTOMS , TARGETING , TEST AND EVALUATION


Subject Categories : Biochemistry
      Medicine and Medical Research
      Pharmacology


Distribution Statement : APPROVED FOR PUBLIC RELEASE